US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioStem Technologies, Inc.

11.46

-0.5170-4.32%

Volume:62.97K

Turnover:720.22K

Market Cap:190.42M

PE:8.12

High:11.98

Open:11.98

Low:11.00

Close:11.98

Loading ...

Overview Company News Filings

Press Release: Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year(R) 2025 Florida Award finalist

Ernst & Young (Ey) US Announces Jason Matuszewski, CEO of Biostem Technologies, as an Entrepreneur of the Year® 2025 Florida Award Finalist

THOMSON REUTERS

Press Release: BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results

Biostem Technologies, Inc. Q1 EPS USD 0.17

THOMSON REUTERS

Press Release: BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

Biostem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million

THOMSON REUTERS

Biostem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of Its Bioretain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BSEM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BSEM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEM\",,,,,undefined,":{"symbol":"BSEM","market":"US","secType":"STK","nameCN":"BioStem Technologies, Inc.","latestPrice":11.458,"timestamp":1748376000000,"preClose":11.975,"halted":0,"volume":62967,"delay":15,"floatShares":16338436,"shares":16618967,"eps":1.411567,"marketStatus":"Not Yet Opened","change":-0.517,"latestTime":"05-27 16:00:00 EDT Delay","open":11.98,"high":11.98,"low":11,"amount":720220.6216750001,"amplitude":0.081837,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.411567,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1748419200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"PINK","adjPreClose":11.975,"volumeRatio":1.393661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BSEM\",,,,,undefined,":{"symbol":"BSEM","floatShares":16338436,"roa":"20.41%","roe":"122.26%","lyrEps":1.947915,"volumeRatio":1.393661,"shares":16618967,"dividePrice":0,"high":11.98,"amplitude":0.081837,"preClose":11.975,"low":11,"week52Low":6.77,"pbRate":"4.01","psRate":"0.57","week52High":28.2565,"institutionHeld":0,"latestPrice":11.458,"eps":1.411567,"divideRate":0,"volume":62967,"delay":15,"ttmEps":1.411567,"open":11.98,"prevYearClose":13.84,"prevWeekClose":11.975,"prevMonthClose":14.12,"prevQuarterClose":8.6,"fiveDayClose":11.97,"twentyDayClose":14.65,"sixtyDayClose":12.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSEM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537948990","title":"Press Release: Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year(R) 2025 Florida Award finalist","url":"https://stock-news.laohu8.com/highlight/detail?id=2537948990","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537948990?lang=en_us&edition=fundamental","pubTime":"2025-05-22 19:04","pubTimestamp":1747911840,"startTime":"0","endTime":"0","summary":"POMPANO BEACH, Fla., May 22, 2025  -- BioStem Technologies, Inc.  , a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, CEO of BioStem is an Ernst & Young LLP  finalist for the prestigious Entrepreneur Of The Year 2025 Florida Award.An independent panel of judges selected Jason Matuszewski, CEO of BioStem Technologies, as one of 25 finalists, recognizing his entrepreneurial spirit, purpose, growth, and lasting impact in creating long-term value.Jason Matuszewski, CEO of BioStem Technologies, commented: \"Being named a finalist for this award is a tremendous honor and a reflection of the incredible work our team performs every day as leaders in the advanced wound care sector. It's humbling to see the impact BioStem and our products have made, not only in improving the lives of patients with chronic wounds nationwide, but also in contributing to the health and ec","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","BK4585","BK4555","03160","R","BK4099","BK4604","BK4007","TM","BK4588","BSEM"],"gpt_icon":0},{"id":"2537994888","title":"Ernst & Young (Ey) US Announces Jason Matuszewski, CEO of Biostem Technologies, as an Entrepreneur of the Year® 2025 Florida Award Finalist","url":"https://stock-news.laohu8.com/highlight/detail?id=2537994888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537994888?lang=en_us&edition=fundamental","pubTime":"2025-05-22 19:00","pubTimestamp":1747911601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA8Q4VZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BSEM"],"gpt_icon":0},{"id":"2535978251","title":"Press Release: BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535978251","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535978251?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:45","pubTimestamp":1747082700,"startTime":"0","endTime":"0","summary":"-- Preliminary net revenue increased 73% to $72.5 million for Q1 2025,-- Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share. -- Reported preliminary Q1 2025 Adjusted EBITDA of $7.8 million. In Q1 2025, BioStem announced key milestones that further solidify its leadership in placental-derived products for wound care. The Company has received Institutional Review Board  approval to initiate a new clinical trial evaluating BioREtain Amnion Chorion  for the treatment of venous leg ulcers . This study is BioStem's third prospective clinical trial and reflects its ongoing commitment to building a rob","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSEM"],"gpt_icon":0},{"id":"2535786022","title":"Biostem Technologies, Inc. Q1 EPS USD 0.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2535786022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535786022?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:00","pubTimestamp":1747080001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nPLX1205D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BSEM"],"gpt_icon":0},{"id":"2527714952","title":"Press Release: BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2527714952","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527714952?lang=en_us&edition=fundamental","pubTime":"2025-04-15 04:18","pubTimestamp":1744661880,"startTime":"0","endTime":"0","summary":"BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million. Million, contributing to a total of $301.8 Million in revenue for 2024. -- Achieves preliminary GAAP net income of $15.5 million, or $0.94 per share,-- Preliminary Q4 2024 Adjusted EBITDA of $11.1 Million. Mr. Matuszewski continued: \"BioStem remains committed to demonstrating the clinical effectiveness of our BioREtain technology. Since the fourth quarter, we have initiated three clinical trials evaluating the efficacy of BioREtain-powered products against the standard of care in patients with diabetic foot ulcers or venous leg ulcers. Separately, we were pleased to announce groundbreaking results in the fourth quarter from a retrospective study on DFU wound closure, which was published in the peer-reviewed International Wound Journal. These trials are aimed at demonstrating clinical superiority for healthcare professionals and payers, w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Press Release: BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSEM"],"gpt_icon":1},{"id":"2527773146","title":"Biostem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2527773146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527773146?lang=en_us&edition=fundamental","pubTime":"2025-04-15 04:14","pubTimestamp":1744661685,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250414:nTUAJ1CB6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BSEM","BK4007"],"gpt_icon":0},{"id":"2501972312","title":"Biostem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of Its Bioretain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®","url":"https://stock-news.laohu8.com/highlight/detail?id=2501972312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501972312?lang=en_us&edition=fundamental","pubTime":"2025-01-08 20:00","pubTimestamp":1736337602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA41LNPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BSEM","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSEM\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747080000000,"name":null,"time":"Post Market","dateTimestamp":1747022400000,"actualEps":null},{"date":"2025-04-14","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1744660800000,"name":null,"time":"Post Market","dateTimestamp":1744603200000,"actualEps":null},{"date":"2024-11-12","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1731445200000,"name":null,"time":"Post Market","dateTimestamp":1731387600000,"actualEps":null},{"date":"2024-08-12","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723492800000,"name":null,"time":"Post Market","dateTimestamp":1723435200000,"actualEps":null},{"date":"2024-05-14","symbol":"BSEM","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715716800000,"name":null,"time":"Post Market","dateTimestamp":1715659200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSEM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BSEM\",market:\"US\",delay:false,,,undefined,":{}}}